Systemic lupus erythematosus and antiphospholipid syndrome: past, present, future
- 作者: Nasonov E.1,2, Reshetnyak T.1, Solovyev S.1, Popkova T.1
-
隶属关系:
- Nasonova Research Institute of Rheumatology
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 95, 编号 5 (2023)
- 页面: 365-374
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/132951
- DOI: https://doi.org/10.26442/00403660.2023.05.202246
- ID: 132951
如何引用文章
全文:
详细
Immune-inflammatory (autoimmune and autoinflammatory) rheumatic diseases are widespread severe chronic inflammatory diseases and also “models” for studying the fundamental mechanisms of pathogenesis and approach to pharmacotherapy of other diseases associated with autoimmunity and/or autoinflammation. Uncontrolled inflammation leading to hypercoagulation forms the basis of “thromboinflammation”, which is considered a universal pathogenetic mechanism of organ involvement in immune-inflammatory rheumatic diseases, as well as in COVID-19 and atherosclerotic vascular lesions (atherothrombosis). Thrombo-inflammatory mechanisms play a crucial role in systemic lupus erythematosus and antiphospholipid syndrome. Russian rheumatology, under the leadership of academician Valentina Alexandrovna Nasonova, greatly contributed to the research of these disorders. This article addresses the current view about the overlapping pathogenetic mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome, the relevance of these studies during the COVID-19 pandemic, and the prospects for antithrombotic and anti-inflammatory therapy.
作者简介
Evgeny Nasonov
Nasonova Research Institute of Rheumatology; Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: nasonov@irramn.ru
ORCID iD: 0000-0002-1598-8360
доктор медицинских наук, профессор академик РАН, научный руководитель, заведующий кафедрой Ревматологии
俄罗斯联邦, Moscow; MoscowTatiana Reshetnyak
Nasonova Research Institute of Rheumatology
Email: nasonov@irramn.ru
ORCID iD: 0000-0003-3552-2522
доктор медицинских наук, профессор зав. лаборат. Тромбовоспаления
俄罗斯联邦, MoscowSergey Solovyev
Nasonova Research Institute of Rheumatology
Email: nasonov@irramn.ru
ORCID iD: 0000-0002-5206-1732
доктор медицинских наук, профессор, научный консультант лаборатории системной красной волчанки
俄罗斯联邦, MoscowTatiana Popkova
Nasonova Research Institute of Rheumatology
Email: nasonov@irramn.ru
ORCID iD: 0000-0001-5793-4689
доктор медицинских наук, нач. отдела системных ревматических заболеваний
俄罗斯联邦, Moscow参考
- Насонов Е.Л. Достижения ревматологии в XXI веке. Научно-практическая ревматология. 2014;52(2):133-40 [Nasonov EL. Achievements in rheumatology in the XXI century. Rheumatology Science and Practice. 2014;52(2):133-40 (in Russian)]. doi: 10.14412/1995-4484-2014-133-140
- Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-18. doi: 10.1182/blood-2018-11-882993
- Wagner DD, Heger LA. Thromboinflammation: From Atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol. 2022;42(9):1103-12. doi: 10.1161/ATVBAHA.122.317162
- Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-67 [Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353-67 (in Russian)]. doi: 10.47360/1995-4484-2020-353-367
- Насонов Е.Л., Решетняк Т.М., Алекберова З.С. Тромботическая микроангиопатия в ревматологии: связь тромбовоспаления и аутоиммунитета. Терапевтический архив. 2020;92(5):4-14 [Nasonov EL, Reshetnyak TM, Alekberova ZS. Thrombotic microangiopathy in rheumatology: the relationship of thrombosis and autoimmunity. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):4-14 (in Russian)]. doi: 10.26442/00403660.2020.05.000697
- Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39
- Тареев Е.М., Виноградова О.М., Насонова В.А., Гусева Н.Коллагенозы. М., 1965 [Tareev EM, Vinogradova OM, Nasonova VA, Guseva NG. Kollagenozy. Moscow, 1965 (in Russian)].
- Насонова В.А. Системная красная волчанка. М.: Медицина, 1972 [Nasonova VA. Sistemnaia krasnaia volchanka. Moscow: Meditsina, 1972 (in Russian)].
- Zamulaeva IA, Lekakh IV, Kiseleva VI, et al. Natural hidden antibodies reacting with DNA or cardiolipin bind to thymocytes and evoke their death. FEBS Lett. 1997;413(2):231-5. doi: 10.1016/s0014-5793(97)00843-0
- Alekberova ZS, Parfanovich MI, Nasonova VA, Zhdanov VM. Molecular pathogenesis of systemic lupus erythematosus. Arch Virol. 1975;47(2):109-21. doi: 10.1007/BF01320551
- Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-14. doi: 10.1038/s41590-020-0677-6
- Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis. 2023. doi: 10.1136/ard-2022-223741
- Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-61 [Nasonov EL, Avdeeva AS. Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence. Rheumatology Science and Practice. 2019;57(4):452-61 (in Russian)]. doi: 10.14412/1995-4484-2019-452-461
- Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18(10):575-90. doi: 10.1038/s41584-022-00826-z
- Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-9. doi: 10.1136/annrheumdis-2018-214819
- Aringer M, Alarcón-Riquelme ME, Clowse M, et al. A glimpse into the future of systemic lupus erythematosus. Ther Adv Musculoskelet Dis. 2022;14:1759720X221086719. doi: 10.1177/1759720X221086719
- Allen ME, Rus V, Szeto GL. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. Trends Mol Med. 2021;27(2):152-71. doi: 10.1016/j.molmed.2020.09.009
- Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565-79. doi: 10.1038/s41584-020-0480-7
- Sciascia S, Roccatello D, Radin M, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi: 10.1038/s41584-021-00710-2
- Насонов Е.Л., Попкова Т.В., Панафидина Т.А. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-28 [Nasonov EL, Popkova TV, Panafidina TA. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021;59(2):119-28 (in Russian)]. doi: 10.47360/1995-4484-2021-119-128
- Антифосфолипидный синдром. По ред. Е.Л. Насонова. Москва: Литтерра, 2004 [Antifosfolipidnyi sindrom. Pod red. EL Nasonova. Moscow: Litterra, 2004 (in Russian)].
- Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Rheumatology Science and Practice. 2014;52(1):56-71 (in Russian)]. doi: 10.14412/1995-4484-2014-56-71
- Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:18005. doi: 10.1038/nrdp.2018.5
- Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 1986;13:486-9.
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x
- Pignatelli P, Ettorre E, Menichelli D, et al. Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105(3):562-72. doi: 10.3324/haematol.2019.221945
- Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: «extra-criteria» manifestations and technical advances. Nat Rev Rheumatol. 2017;13(9):548-60. doi: 10.1038/nrrheum.2017.124
- Насонова В.А., Алекберова З.С., Калашникова Л.А., Решетняк Т.М. Поздняя диагностика системной красной волчанки с антифосфолипидным синдромом. Терапевтический архив. 1997;11:50-4 [Nasonova VA, Alekberova ZS, Kalashnikova LA, Reshenyak TM. Late diagnosis of systemic lupus erythematosus with antiphospholipid syndrome. Terapevticheskii Arkhiv (Ter. Arkh.). 1997;11:50-4 (in Russian)].
- Решетняк Т.М., Котельникова Т.Н., Калашникова Л.А., и др. Клинико-иммунологические проявления первичного и вторичного антифосфолипидного синдрома. Научно- практическая ревматология. 2004;42(4):15-23 [Reshetnyak TM, Kotelnikova TN, Kalashnikova LA, et al. Clinical and immunological features of primary and secondary antiphospholipid syndrome. Rheumatology Science and Practice. 2004;42(4):15-23 (in Russian)]. doi: 10.14412/1995-4484-2004-796
- Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000–2004: relation to disease activity and damage accrual. Lupus. 2007;16(5):309-17. doi: 10.1177/0961203307077987
- Решетняк Т.М., Алекберова З.С. Исследование антифосфоли.идного синдрома: основные этапы и достижения. В кн.: Достижения ревматологии в начале XXI века. Под ред. aкад. Е.Л. Насонова. Москва, ИМА-ПРЕСС, 2018; c. 122-37 [Reshetniak TM, Alekberova ZS. Issledovaniie antifosfolipidnogo sindroma: osnovnyie etapy i dostizheniia. V kn.: Dostizheniia revmatologii v nachale XXI veka. Pod red. akad. EL Nasonova. Moscow, IMA-PRESS, 2018; p. 122-37 (in Russian)].
- Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014;48-49:20-5. doi: 10.1016/j.jaut.2014.01.006
- Решетняк Т.М., Чельдиева Ф.А., Нурбаева К.С., и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21 [Reshetnyak TM, Cheldieva FA, Nurbayeva KS, et al. Antiphospholipid syndrome: diagnosis, development mechanism, therapy issues. Thrombosis, Hemostasis and Rheology. 2020;(4):4-21 (in Russian)]. doi: 10.25555/THR.2020.4.0940
- Cervera R, Rodríguez-Pintó I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun. 2018;92:1-11. doi: 10.1016/j.jaut.2018.05.007
- Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol. 2022;44(3):347-62. doi: 10.1007/s00281-022-00916-w
- Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, Hernandez-Juarez J. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. Clin Appl Thromb Hemost. 2022;28:10760296221088576. doi: 10.1177/10760296221088576
- Serrano M, Espinosa G, Serrano A, Cervera R. Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. Int J Mol Sci. 2022;23(9):4946. doi: 10.3390/ijms23094946
- Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost. 2021;19(3):607-16. doi: 10.1111/jth.15082
- Tan Y, Liu Q, Li Z, et al. Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy. Autoimmun Rev. 2022;21(8):103130. doi: 10.1016/j.autrev.2022.103130
- van Mourik DJM, Salet DM, Middeldorp S, et al. The role of the intestinal microbiome in antiphospholipid syndrome. Front Immunol. 2022;13:954764. doi: 10.3389/fimmu.2022.954764
- Yan H, Li B, Su R, et al. Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome. Front Immunol. 2022;13:873644. doi: 10.3389/fimmu.2022.873644
- van den Hoogen LL, Bisoendial RJ. B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy? J Clin Med. 2022;12(1):18. doi: 10.3390/jcm12010018
- Cecchi I, Radin M, Rodríguez-Carrio J, et al. Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. Expert Rev Clin Immunol. 2021;17(4):395-406. doi: 10.1080/1744666X.2021.1901581
- Hisada R, Kato M, Sugawara E, et al. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation. J Thromb Haemost. 2019;17(7):1134-43. doi: 10.1111/jth.14427
- Arantes FT, Mazetto BM, Saraiva SS, et al. Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome. J Thromb Thrombolysis. 2020;50(4):772-81. doi: 10.1007/s11239-020-02155-y
- Long Y, Li W, Feng J, et al. Follicular helper and follicular regulatory T cell subset imbalance is associated with higher activated B cells and abnormal autoantibody production in primary anti-phospholipid syndrome patients. Clin Exp Immunol. 2021;206(2):141-52. doi: 10.1111/cei.13647
- McDonnell T, Wincup C, Buchholz I, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020;39:100610. doi: 10.1016/j.blre.2019.100610
- Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus disease 2019 (COVID-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian)]. doi: 10.14412/1995-4484-20
- Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci. 2022;92(4):398-403. doi: 10.1134/S1019331622040062
- Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28-33. doi: 10.1038/s41591-020-01202-8
- Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-73. doi: 10.1056/NEJMra2026131
- McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021;17(3):145-57. doi: 10.1038/s41584-020-00571-1
- Shi H, Zuo Y, Navaz S, et al. Endothelial Cell-Activating Antibodies in COVID-19. Arthritis Rheumatol. 2022;74(7):1132-8. doi: 10.1002/art.42094
- Hollerbach A, Müller-Calleja N, Pedrosa D, et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost. 2021;19(9):2335-47. doi: 10.1111/jth.15455
- Zuniga M, Gomes C, Carsons SE, et al. Autoimmunity to annexin A2 predicts mortality among hospitalised COVID-19 patients. Eur Respir J. 2021;58(4):2100918. doi: 10.1183/13993003.00918-2021
- Doevelaar AAN, Bachmann M, Hölzer B, et al. Generation of Inhibitory Autoantibodies to ADAMTS13 in Coronavirus Disease 2019. medRxiv. 2021.03.18.21253869. doi: 10.1101/2021.03.18.21253869
- Lee SJ, Kim JE, Han KS, Kim HK. Thrombotic risk of reduced ADAMTS13 activity in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis. 2016;27(8):907-12. doi: 10.1097/MBC.0000000000000512
- Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol. 2022;22(2):77-84. doi: 10.1038/s41577-021-00665-1
- Zuo Y, Yalavarthi S, Navaz SA, et al. Autoantibodies stabilize neutrophil extracellular traps in COVID-19. JCI Insight. 2021;6(15):e150111. doi: 10.1172/jci.insight.150111
- Zuo Y, Yalavarthi S, Gockman K, et al. Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome. Arthritis Rheumatol. 2020;72(12):2130-5. doi: 10.1002/art.41460
- Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-24. doi: 10.1126/science.abc6027
- Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. doi: 10.1126/science.abd4570
- Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4585. doi: 10.1126/science.abd4585
- Beydon M, Nicaise-Roland P, Mageau A, et al. Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study. Sci Rep. 2022;12(1):11244. doi: 10.1038/s41598-022-15508-9
- Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21(12):1506-16. doi: 10.1038/s41590-020-00814-z
- Farris AD, Guthridge JM. Overlapping B cell pathways in severe COVID-19 and lupus. Nat Immunol. 2020;21(12):1478-80. doi: 10.1038/s41590-020-00822-z
- Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis. 2019;26(5):376-86. doi: 10.1053/j.ackd.2019.08.012
- Tiwari NR, Phatak S, Sharma VR, Agarwal SK. COVID-19 and thrombotic microangiopathies. Thromb Res. 2021;202:191-8. doi: 10.1016/j.thromres.2021.04.012
- Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat Rev Rheumatol. 2022;18(3):146-57. doi: 10.1038/s41584-021-00739-3
- Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089
- Соловьев С.К., Асеева Е.А., Попкова Т.В., и др. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14 [Solovyev SK, Aseeva EA, Popkova TV, et al. Systemic lupus erythematosus: New horizons for diagnosis and therapy. Rheumatology Science and Practice. 2020;58(1):5-14 (in Russian)]. doi: 10.14412/1995-4484-2020-5-14
- Насонов Е.Л., Соловьев С.К., Аршинов А.В. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412 [Nasonov EL, Soloviev SK, Arshinov AV. Systemic lupus erythematosus: history and modernity. Rheumatology Science and Practice. 2022;60(4):397-412 (in Russian)]. doi: 10.47360/1995-4484-2022-397-412
- Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: New drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl. 5):v69-81. doi: 10.1093/rheumatology/keaa403
- Arriens C, Teng YKO, Ginzler EM, et al. Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis. Arthritis Care Res (Hoboken). 2022. doi: 10.1002/acr.25007
- Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annu Rev Med. 2023;74:339-52. doi: 10.1146/annurev-med-043021-032611
- Szelinski F, Lino AC, Dörner T. B cells in systemic lupus erythematosus. Curr Opin Rheumatol. 2022;34(2):125-32. doi: 10.1097/BOR.0000000000000865
- Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: Advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179-99. doi: 10.1038/s41573-020-00092-2
- Насонов Е.Л., Бекетова Т.В., Ананьева Л.П., и др. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40 [Nasonov EL, Beketova TV, Ananyeva LP, et al. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1-40 (in Russian)]. doi: 10.14412/1995-4484-2019-3-40
- Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69-77. doi: 10.1038/nbt.2076
- Насонов Е.Л., Решетняк Т.М., Денисов Л.Н., Соловьев С.К. Белимумаб: прогресс в лечении системной красной волчанки. Научно-практическая ревматология. 2012;50(5):13-9 [Nasonov EL, Reshetnyak TM, Denisov LN, Solovyov SK. Belimumab: Advances in drug therapy for systemic lupus erythematosus. Rheumatology Science and Practice. 2012;50(5):13-9 (in Russian)]. doi: 10.14412/1995-4484-2012-1174
- Насонов Е.Л., Попкова Т.В., Лила А.М. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-83 [Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367-83 (in Russian)]. doi: 10.47360/1995-4484-2021-367-383
- Hiepe F, Dörner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol. 2011;7(3):170-8. doi: 10.1038/nrrheum.2011.1
- Ostendorf L, Burns M, Durek P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149-55. doi: 10.1056/NEJMoa2023325
- Pleguezuelo DE, Díaz-Simón R, Cabrera-Marante O, et al. Case Report: Resetting the Humoral Immune Response by Targeting Plasma Cells With Daratumumab in Anti-Phospholipid Syndrome. Front Immunol. 2021;12:667515. doi: 10.3389/fimmu.2021.667515
- Orvain C, Boulch M, Bousso P, et al. Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases? Arthritis Rheumatol. 2021;73(11):1954-65. doi: 10.1002/art.41812
- Mougiakakos D, Krönke G, Völkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567-9. doi: 10.1056/NEJMc2107725
- Goulden B, Isenberg D. Anti-IFNαR MAbs for the treatment of systemic lupus erythematosus. Expert Opin Biol Ther. 2021;21(4):519-28. doi: 10.1080/14712598.2021.1841164
- Насонов Е.Л., Авдеева А.С., Попкова Т.В. Новые возможности фармакотерапии системной красной волчанки: перспективы применения анифролумаба (моноклональные антитела к рецепторам интерферона типа I). Научно-практическая ревматология. 2021;59(5):537-46 [Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537-46 (in Russian)]. doi: 10.47360/1995-4484-2021-537-546
- Насонов Е.Л., Лила А.М. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16 (in Russian)]. doi: 10.14412/1995-4484-2019-8-16
- Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133-45. doi: 10.1038/s41584-021-00726-8
- Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10143):222-31. doi: 10.1016/S0140-6736(18)31363-1
- Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021-23361-z
- Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-304. doi: 10.1136/annrheumdis-2019-215213
- Dima A, Jurcut C, Chasset F, et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001. doi: 10.1177/1759720X211073001
- Решетняк Т.М., Нурбаева К.С. Прямые оральные антикоагулянты при антифосфолипидном синдроме. Научно-практическая ревматология. 2020;58(6):708-15 [Reshetnyak TM, Nurbaeva KS. Direct-acting oral anticoagulants in antiphospholipid syndrome. Rheumatology Science and Practice. 2020;58(6):708-15 (in Russian)]. doi: 10.47360/1995-4484-2020-708-715
- Kello N, Khoury LE, Marder G, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Semin Arthritis Rheum. 2019;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005
- Hussain H, Tarantino MD, Chaturvedi S, et al. Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Adv. 2022;6(4):1271-7. doi: 10.1182/bloodadvances.2021005657
- Ng N, Powell CA. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease. J Clin Med. 2021;10(10):2188. doi: 10.3390/jcm10102188
- Vitiello A, La Porta R, D'Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. 2021;82(4):264-9. doi: 10.1016/j.humimm.2021.01.007
- Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. J Autoimmun. 2022;128:102813. doi: 10.1016/j.jaut.2022.102813
- Serrano M, Espinosa G, Serrano A, Cervera R. COVID-19 and the antiphospholipid syndrome. Autoimmun Rev. 2022;21(12):103206. doi: 10.1016/j.autrev.2022.103206
- Cohen H, Isenberg DA. How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. Blood. 2021;137(3):299-309. doi: 10.1182/blood.2020004942
- Tumian NR, Hunt BJ. Clinical Management of Thrombotic Antiphospholipid Syndrome. J Clin Med. 2022;11(3):735. doi: 10.3390/jcm11030735
- Erkan D. Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome. Arthritis Rheumatol. 2021;73(10):1780-90. doi: 10.1002/art.41891
- Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-79. doi: 10.1136/annrheumdis-2021-221733
- Murakami N, Hayden R, Hills T, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2023;19(1):38-52. doi: 10.1038/s41581-022-00642-4.
- van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9.